- Home
- AMGN vs UBS Comparison
AMGN vs UBS Comparison
Compare AMGN & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- UBS
- Stock Information
- Founded
- AMGN 1980
- UBS 1862
- Country
- AMGN United States
- UBS Switzerland
- Employees
- AMGN N/A
- UBS N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- UBS Major Banks
- Sector
- AMGN Health Care
- UBS Finance
- Exchange
- AMGN Nasdaq
- UBS Nasdaq
- Market Cap
- AMGN 150.8B
- UBS 122.4B
- IPO Year
- AMGN N/A
- UBS N/A
- Fundamental
- Price
- AMGN $292.00
- UBS $38.03
- Analyst Decision
- AMGN Hold
- UBS Buy
- Analyst Count
- AMGN 15
- UBS 3
- Target Price
- AMGN $313.57
- UBS N/A
- AVG Volume (30 Days)
- AMGN 2.0M
- UBS 1.9M
- Earning Date
- AMGN 11-04-2025
- UBS 10-29-2025
- Dividend Yield
- AMGN 3.26%
- UBS 1.95%
- EPS Growth
- AMGN 110.88
- UBS 84.33
- EPS
- AMGN 12.23
- UBS 2.21
- Revenue
- AMGN $34,917,000,000.00
- UBS $48,193,000,000.00
- Revenue This Year
- AMGN $8.90
- UBS $3.51
- Revenue Next Year
- AMGN $1.79
- UBS $3.55
- P/E Ratio
- AMGN $23.88
- UBS $16.53
- Revenue Growth
- AMGN 12.88
- UBS 2.09
- 52 Week Low
- AMGN $253.30
- UBS $25.75
- 52 Week High
- AMGN $335.88
- UBS $42.57
- Technical
- Relative Strength Index (RSI)
- AMGN 50.00
- UBS 38.77
- Support Level
- AMGN $293.14
- UBS $37.91
- Resistance Level
- AMGN $294.81
- UBS $39.21
- Average True Range (ATR)
- AMGN 5.57
- UBS 0.43
- MACD
- AMGN -0.94
- UBS -0.06
- Stochastic Oscillator
- AMGN 23.99
- UBS 15.54
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About UBS UBS Group AG Registered
The core of UBS is its global wealth management business focusing on high and ultra-high-net-worth individuals. UBS is also a conventional retail and commercial bank in its Swiss home market. Its investment bank and asset management businesses support its wealth management operations, but also leverage its strength in wealth management to serve third-party clients.